Geneoscopy was just cleared to accept human samples for diagnostic testing by the Center for Medicare and Medicaid Services, an essential step for research at it’s still newish labs.
Andrew Barnell, Geneoscopy CEO
“It’s a critical part of our business,” CEO Andrew Barnell told the 4thEst8. “The lab has actually been open for about 18 months… (CLIA certification) is just one of the gating items that are required to ultimately deliver our test to patients.”
The St. Louis-based Geneoscopy was founded in 2015. The company is developing a screening methodology to noninvasively diagnose colorectal cancer using bio-markers in stool samples. The screening technology examines RNA in a stool sample to detect the cancer, but this simple test is just the first of what Barnell says will be a platform of tests. Broadening this technology could be used to detect, prevent, and guide treatment of a wide variety of gastrointestinal diseases.
The company has 40 full time employees, mostly scientists. Last November it closed a $105M Series B led by Lightchain Capital and NT Investments with participation from Morningside Ventures, Labcorp, Cultivation Capital, BioGenerator Ventures and Innovatus Capital Partners. Prior to that, it raised a total of $7.9M, mostly from a 2019 Series A. Other investors include Missouri Technology Corporation, Billiken Angels Network, the Dorm Room Fund and individual investor Rodger Riney.
Links:
On the 4thEst8:
